Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.
2.

Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.

Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.

Liver Transpl. 2003 Oct;9(10):1079-85.

3.

Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy.

Rodríguez-Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK.

Am J Transplant. 2013 Jan;13(1):239. doi: 10.1111/j.1600-6143.2012.04306.x. Epub 2012 Nov 5. No abstract available.

4.

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.

Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.

Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.

5.

Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results.

Conti DJ, Petrov R, Elbalhoul O, Gallichio M.

Transpl Immunol. 2008 Nov;20(1-2):12-3. doi: 10.1016/j.trim.2008.08.011. Epub 2008 Sep 13.

PMID:
18793727
6.

Critical relevance of early calcineurin-inhibitor exposure for long-term renal function after liver transplantation: response to letter by Rodríguez-Perálvarez et al.

Schlitt HJ, Mertens M, Fischer L.

Am J Transplant. 2013 Jan;13(1):240. doi: 10.1111/j.1600-6143.2012.04305.x. No abstract available.

7.

Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details….

McKenna GJ, Trotter JF.

Am J Transplant. 2012 Mar;12(3):521-2. doi: 10.1111/j.1600-6143.2011.03922.x. Epub 2012 Feb 2. No abstract available.

8.

Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.

DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.

Liver Transpl. 2008 May;14(5):651-9. doi: 10.1002/lt.21429.

9.

Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety.

Ju WQ, Guo ZY, Liang WH, Wu LW, Tai Q, Hu AB, Han M, Zhu XF, He X.

Exp Clin Transplant. 2012 Apr;10(2):132-5.

10.

Considerations in sirolimus use in the early and late post-transplant periods.

Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.

Expert Opin Drug Saf. 2009 Jul;8(4):421-34. doi: 10.1517/14740330903037156. Review.

PMID:
19522662
11.

Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.

Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.

Transplant Proc. 2011 Jul-Aug;43(6):2187-90. doi: 10.1016/j.transproceed.2011.06.055.

PMID:
21839229
12.

Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.

Yang YJ, Li LX, He Q, Fan H, Jin ZK, Lang R, Kou JT, Li P, Xie DH, Chen DZ.

Hepatobiliary Pancreat Dis Int. 2007 Aug;6(4):376-8.

13.

Sirolimus and cardiac transplantation: is it the "magic bullet"?

Mudge GH Jr.

Circulation. 2007 Dec 4;116(23):2666-8. No abstract available.

14.

[Minimize kidney failure in transplantation patients with proliferation signal inhibitors].

Glowacki F, Dharancy S, Noël C, Hazzan M.

Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S253-6. doi: 10.1016/S0399-8320(09)73162-8. French.

15.

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.

J Heart Lung Transplant. 2005 Dec;24(12):2129-36.

PMID:
16364861
16.

Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients.

Martínez-Mier G, Méndez-López MT, Estrada-Oros J, Budar-Fernandez LF, Soto-González JI, Méndez-Machado GF, Viñas Dozal JC.

Arch Med Res. 2006 Jul;37(5):635-8.

PMID:
16740435
17.

Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant.

Mancuso A, Perricone G.

Transpl Int. 2015 Apr;28(4):502. doi: 10.1111/tri.12477. No abstract available.

18.

Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant.

Cholongitas E, Burra P.

Transpl Int. 2015 Apr;28(4):503-4. doi: 10.1111/tri.12496. No abstract available.

19.

Up-date on renal fibrosis: a time for action.

Wardle EN.

Saudi J Kidney Dis Transpl. 2007 Jun;18(2):262. No abstract available.

20.

Surgical oncology: Good things don't come to those who watchfully wait.

Villanueva MT.

Nat Rev Clin Oncol. 2011 Jun 7;8(7):386. doi: 10.1038/nrclinonc.2011.84. No abstract available.

PMID:
21647197

Supplemental Content

Support Center